Downregulation of RIPK4 Expression Inhibits Epithelial-Mesenchymal Transition in Ovarian Cancer through IL-6

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• The role of Receptor-interacting protein kinase 4 (RIPK4) in ovarian cancer (OC) remains unclear.
• RIPK4 is implicated in various cancer types, necessitating investigation into its specific function in OC progression.

Purpose of the Study:

• To elucidate the role and molecular mechanisms of RIPK4 in ovarian cancer.
• To determine if RIPK4 expression correlates with patient survival and metastatic potential.
• To explore RIPK4 as a potential diagnostic and therapeutic target for OC.

Main Methods:

• Gene Expression Profiling Interactive Analysis (GEPIA)
• Reverse Transcription Polymerase Chain Reaction (RT-PCR)
• Immunohistochemical analysis
• Functional experiments involving RIPK4 downregulation
• Gene Set Enrichment Analysis (GSEA) on TCGA database
• Western blotting for key protein markers
• Interleukin-6 (IL-6) rescue experiments

Main Results:

• RIPK4 expression is significantly higher in OC tissues and cells compared to normal controls.
• Increased RIPK4 expression in OC correlates with significantly worse overall survival (HR 1.5, P = 0.001).
• RIPK4 downregulation inhibits OC cell metastatic behaviors and epithelial-mesenchymal transition (EMT).
• RIPK4 silencing reduces vimentin, N-cadherin, and Twist, while increasing E-cadherin and decreasing IL-6/STAT3 levels.
• IL-6 addition rescues the suppressive effect of RIPK4 knockdown on EMT, indicating IL-6 mediates RIPK4's role in EMT.

Conclusions:

• RIPK4 downregulation restrains EMT in OC by inhibiting the IL-6 signaling pathway.
• RIPK4 represents a potential novel diagnostic and therapeutic target for improving OC patient outcomes.
• Targeting RIPK4 could offer a new strategy to combat ovarian cancer progression and metastasis.